Programmed cell death-1 (PD-1) was discovered in 1992, and studies targeting the immune checkpoints CTLA-4, PD-1, and programmed cell death-Ligand 1 (PD-L1) have led to breakthroughs in a variety of cancer types. This evidence concerns the gene PDCD1 and cancer.